Fluocinonide cream is indicated for the relief of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
Glenmark Generics, USA, the subsidiary of Glenmark Generics, has been granted final approval from the United States Food and Drug Administration (US FDA) for its abbreviated new drug application (ANDA) for Fluocinonide cream USP 0.1 per cent, the generic version of Vanos cream by Medicis.
Fluocinonide cream is indicated for the relief of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. According to IMS Health sales data for the 12 month period ending March 2014, Fluocinonide cream garnered annual sales of approximately $103 million.
Glenmark’s current portfolio consists of 93 products authorised for distribution in the US marketplace and 71 ANDA’s pending approval with the US FDA.
EP News Bureau– Mumbai
- Advertisement -
